Supercharging Immunotherapy

More about us

HOOKIPA announces clinical collaboration

HOOKIPA announces clinical collaboration with Merck & Co., Inc., Kenilworth, NJ., USA to evaluate HB-200 in combination with KEYTRUDA® (pembrolizumab) in patients with advanced head and neck cancers

Press Release

KOL Roundtable

CD8+ T cells play a key role in fighting cancer. Learn more about why antigen-specificity, quantity and quality matter in developing effective immunotherapies. Follow the link to watch video.

Watch video

Driving a robust T cell response

Preliminary immunogenicity data presented at AACR show our lead oncology candidates, HB-201 and HB-202, induce a strong antigen-specific T cell response, with a robust increase in HPV16+-specific T cells after just one dose.

Read more

A pioneering arenavirus platform

Our proprietary, flexible platform can engineer arenaviral therapeutics that mobilize and amplify targeted T cells and antibodies, the body’s natural infection killers, to fight or prevent serious disease.

Read more

Our Mission

We work to reprogram the immune system to more effectively combat cancer and infectious diseases. We do this by using a technology that “supercharges” the natural ability of the immune system to combat disease.

read more

Our Pipeline

immuno-oncology
infectious disease
our pipeline

Careers

The source of HOOKIPA’s strength lies in our people and the skills and experience that they bring. We want to continue to grow fast as a company and nurture a respectful and diverse culture that encourages teamwork. Attracting and retaining the best people is essential to achieve this. Please get in touch with us to find out more about our career opportunities.

read more